Status:
ACTIVE_NOT_RECRUITING
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Lead Sponsor:
European Institute of Oncology
Conditions:
Lobular Breast Carcinoma
Lobular in Situ Breast Carcinoma
Eligibility:
FEMALE
18-99 years
Brief Summary
This is a cross-sectional and retrospective study of a cohort of patients with invasive lobular breast cancer (LBC) or in situ lobular neoplasia (LIN3). The main endpoint is the relative frequency of...
Detailed Description
Pathogenic or likely pathogenic variants (commonly referred to as mutations) in high-penetrance breast cancer (BC) susceptibility genes increase the risk of BC more than fourfold. Germline mutations i...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- All LBC observed retrospectively at the European Institute of Oncology, with a proved diagnosis of LBC (biopsy or operated)
- Patients with blood available in biobank Exclusion criteria
- Patients with a previous cancer (except skin basal cell carcinoma)
- Patients with ductal or mixed BC
Exclusion
Key Trial Info
Start Date :
May 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 16 2026
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT05410951
Start Date
May 16 2022
End Date
May 16 2026
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
European Institute of Oncology
Milan, Italy